Leflunomide is an oral disease-modifying antirheumatic drug administered to patients with rheumatoid and psoriatic arthritis. This drug inhibits dihydroorotate dehydrogenase, an enzyme critical in the production of intracellular pyrimidines, and down-regulates tumor necrosis factor-alfa activity. Leflunomide has demonstrated usefulness in treating cutaneous psoriasis along with other dermatologic and rheumatologic conditions.Le texte complet de cet article est disponible en PDF.
Key words : atopic dermatitis, dihydroorotate dehydrogenase, leflunomide, psoriasis, psoriatic arthritis, rheumatoid arthritis, tumor necrosis factor-alfa
| Funding sources: None.
| Conflicts of interest: None declared.